Modulation of inflammatory gene transcripts in psoriasis vulgaris: Differences between ustekinumab and etanercept

Abstract excerpt

Since the advent of biologic therapy for psoriasis in 2003, continued development of cytokine antagonists has yielded progressively better clinical outcomes, as assessed using the Psoriasis Area and Severity Index (PASI) or Patient's Global Assessment. In addition, more targeted therapies seemingly afford better patient adherence. For example, the anti–IL-12/23 mAb ustekinumab has demonstrated much better “drug...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cytokine Signaling Pathways and Interactions
• Share to Immunodeficiency and Autoimmune Disorders
• Share to Psoriasis: Treatment and Pathogenesis